BIOPHYTIS (EPA:ALBPS) - Results of Biophytis SARA-INT Phase 2 Trial with Sarconeos (BIO101) in Sarcopenia will be Released by August 2021

Transparency directive : regulatory news

30/06/2021 23:00

Press release

Results of Biophytis SARA-INT Phase 2 Trial with Sarconeos
(BIO101) in Sarcopenia will be Released by August 2021

Paris, France, Cambridge (Massachusetts, United States), June 30 2021, 11 pm
CET - Biophytis SA (Nasdaq CM: BPTS, Euronext Growth Paris: ALBPS),
("Biophytis" or the "company"),a clinical- stage biotechnology company focused
on the development of therapeutics that are aimed at slowing the degenerative
processes associated with aging and improving functional outcomes for patients
suffering from age-related diseases, including severe respiratory failure in
patients suffering from COVID-19 today announces topline results for SARA-INT
phase 2 study will be released in August 2021. The full results with complete
details will be presented during the digital ICSFR scientific & medical
conference, next September 29-October 2 2021.

The objective of the SARA-INT Phase 2 study is to evaluate the efficacy and
safety of Sarconeos (BIO101) in a randomized placebo-controlled study in
patients over 65 years suffering from sarcopenia and considered at high risk of
mobility disability. The primary endpoint of SARA-INT is patients' mobility
disability as measured by the gait-speed over the 400-meter walk test
(400MWT).

The multicenter double-blind, interventional study recruited a total of 233
patients in 22 centers in Belgium and the US who were dosed orally at 175 mg
b.i.d. and 350 mg b.i.d. with Sarconeos (BIO101) through a 26-week period. 196
of those patients have completed the trial despite the COVID-19 pandemic last
December 2020.

About BIOPHYTIS
Biophytis SA is a clinical-stage biotechnology company specialized in the
development of therapeutics that are aimed at slowing the degenerative
processes associated with aging and improving functional outcomes for patients
suffering from age-related diseases, including severe respiratory failure in
patients suffering from COVID-19.Sarconeos (BIO101), our leading drug
candidate, is a small molecule, administered orally, being developed as a
treatment for sarcopenia in a Phase 2 clinical trial in the United States and
Europe (SARA-INT). It is also being studied in a clinical two-part Phase 2-3
study (COVA) for the treatment of severe respiratory manifestations of COVID-19
in Europe, Latin America, and the US. A pediatric formulation of Sarconeos
(BIO101) is being developed for the treatment of Duchenne Muscular Dystrophy
(DMD). The company is based in Paris, France, and Cambridge, Massachusetts.The
company's common shares are listed on Euronext Growth (Ticker: ALBPS
-ISIN:FR0012816825) and ADSs are listed on Nasdaq Capital Market (Ticker BPTS -
ISIN: US09076G1040). For more information visit www.biophytis.com

Disclaimer
This press release contains forward-looking statements. Forward-looking
statements include all statements that are not historical facts. In some cases,
you can identify these forward-looking statements by the use of words such as
"outlook," "believes," "expects," "potential," "continues," "may," "will,"
"should," "could," "seeks," "predicts," "intends," "trends," "plans,"
"estimates," "anticipates" or the negative version of these words or other
comparable words. These forward-looking statements include statements regarding
Biophytis' anticipated timing for its various Sarconeos (BIO101) clinical
trials and expectations regarding commercialization. Such forward-looking
statements are based on assumptions that Biophytis considers to be reasonable.
However, there can be no assurance that the statements contained in such
forward-looking statements will be verified, which are subject to various risks
and uncertainties including, without limitation, delays in patient recruitment
or retention, interruptions in sourcing or supply chain, its ability to obtain
the necessary regulatory authorizations, COVID- 19-related delays, and the
impact of the current pandemic on the Company's clinical trials. The
forward-looking statements contained in this press release are also subject to
risks not yet known to Biophytis or not currently considered material by
Biophytis. Accordingly, there are or will be important factors that could cause
actual outcomes or results to differ materially from those indicated in these
statements. Please refer to the "Risk Factors" section of the Company's Annual
2020 Report available on BIOPHYTIS website (www.biophytis.com) and to the risks
discussed in the Company's registration statement on Form F-1 and other reports
filed with the Securities and Exchange Commission (the "SEC"). We undertake no
obligation to publicly update or review any forward-looking statement, whether
as a result of new information, future developments or otherwise, except as
required by law.

Biophytis Contact for Investor Relations
Evelyne Nguyen, CFO
evelyne.nguyen@biophytis.com

Media contact
Life Sci Advisors
Sophie Baumont
E: sophie@lifesciadvisors.com
T: +33 6 27 74 74 49

Investor Relations
LifeSci Advisors, LLC
Chris Maggos
E: chris@lifesciadvisors.com

BIOPHYTIS's latest news

14/05/2024 07:00

BIOPHYTIS (EPA:ALBPS) - Results of Biophytis SARA-INT Phase 2 Trial with Sarconeos (BIO101) in Sarcopenia will be Released by August 2021

Transparency directive : regulatory news

BIOPHYTIS's latest news

Other stories